- Home
- TACT vs MREO Comparison
TACT vs MREO Comparison
Compare TACT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TACT | MREO |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4M | 50.3M |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | TACT | MREO |
|---|---|---|
| Price | $5.56 | $0.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $1.97 |
| AVG Volume (30 Days) | 22.4K | ★ 826.3K |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.88 | 16.67 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $3.74 | N/A |
| P/E Ratio | $80.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.06 | $0.20 |
| 52 Week High | $6.02 | $2.37 |
Technical Indicators
Market Signals| Indicator | TACT | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 67.19 | 42.82 |
| Support Level | $4.72 | $0.27 |
| Resistance Level | $6.01 | $0.35 |
| Average True Range (ATR) | 0.32 | 0.02 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 88.23 | 25.85 |
Price Performance
Historical ComparisonAbout TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).